ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat < sup > ® < /sup > significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS † treatment

ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat < sup > ® < /sup > significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS † treatment
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news